All In Biotech

Drug Trial Radar · NCT07446855

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Mar 17, 2026

Primary completion

Mar 29, 2030

Study completion Mar 29, 2030

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this modular, first trial in human study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ascending dose levels (DLs) of AZD4956 monotherapy and in combination with other anti-cancer agents in participants with advanced/metastatic solid tumours with homologous recombination repair (HRR) deficiencies.

Conditions

  • Solid Tumours

Interventions

  • AZD4956Drug

    AZD4956 will be administered orally.

  • SaruparibDrug

    Saruparib will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A and B: Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: From Screening (Day -28) to follow-up (up to 3.5 years)
  2. Part B: Progression free survival (PFS)Time frame: Up to 3.5 years
  3. Part A - Number of participants with dose-limiting toxicities (DLTs)Time frame: Up to 28 days

Locations

19 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Providence, Rhode Island · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Fairfax, Virginia · Recruiting

  • Research Site

    Melbourne, Australia · Recruiting

  • Research Site

    Westmead, Australia · Recruiting

  • Research Site

    Chūōku, Japan · Recruiting

  • Research Site

    Kashiwa, Japan · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Barcelona, Spain · Recruiting

  • Research Site

    Barcelona, Spain · Recruiting

  • Research Site

    Barcelona, Spain · Not yet recruiting

  • Research Site

    Logroño, Spain · Not yet recruiting

  • Research Site

    Pozuelo de Alarcón, Spain · Not yet recruiting

  • Research Site

    Seville, Spain · Not yet recruiting

  • Research Site

    Cambridge, United Kingdom · Recruiting

  • Research Site

    London, United Kingdom · Not yet recruiting

  • Research Site

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.